A major problem in drug development is substance insolubility. Even when highly effective, a large proportion of drugs can only be delivered by injection or intravenously rather than taken orally and intestinally absorbed.
Hydroxyapatite is a major body component, used widely in internal applications such as bone filler or implant coating, due to its excellent biocompatibility, and ability to improve the body’s acceptance of foreign materials.
Sangi’s researchers found that coating with hydroxyapatite improves the solubility and intestinal absorption of poorly soluble and/or poorly absorbed drugs, suggesting that drugs currently available only by injection or intravenously could in future be administered in tablet or capsule form.

Moreover experiments show Sangi’s proprietary technology not only improves drug solubility, but may also improve drug effectiveness while reducing unwanted side-effects. More work is needed, but if the technology proves successful, Sangi’s drug delivery system may reduce patients’ need for hospital visits and make a significant contribution to patient quality of life.